Related references
Note: Only part of the references are listed.Adhesion molecules in multiple myeloma oncogenesis and targeted therapy
Maroun Bou Zerdan et al.
International Journal of Hematologic Oncology (2022)
Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma
Ellen Leich et al.
BLOOD CANCER JOURNAL (2021)
O-GlcNAcylation homeostasis controlled by calcium influx channels regulates multiple myeloma dissemination
Parinya Samart et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Upregulated expression and function of theα4β1 integrin in multiple myeloma cells resistant to bortezomib
Silvia Sevilla-Movilla et al.
JOURNAL OF PATHOLOGY (2020)
Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study
Michael E. O'Dwyer et al.
BLOOD (2020)
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
Leo Rasche et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Naoki Hosen et al.
NATURE MEDICINE (2017)
The ADAMs family of proteases as targets for the treatment of cancer
Maeve Mullooly et al.
CANCER BIOLOGY & THERAPY (2016)
Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
E. Leich et al.
BLOOD CANCER JOURNAL (2013)
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion
Paola Neri et al.
BLOOD (2011)
Adhesion molecules-The lifelines of multiple myeloma cells
Ben-Zion Katz
SEMINARS IN CANCER BIOLOGY (2010)
Extracellular matrix in bone marrow can mediate drug resistance in myeloma
T Vincent et al.
LEUKEMIA & LYMPHOMA (2005)
Share Paper
